HOME > Articles >

Korean J Gastroenterol  <  Volume 72(5); 2018 <  Articles

The Korean Journal of Gastroenterology 2018; 72(5): 245-251  https://doi.org/10.4166/kjg.2018.72.5.245
Helicobacter pylori Eradication Therapy and Gastric Cancer Prevention
Il Ju Choi
Center for Gastric Cancer, National Cancer Center, Goyang, Korea
Correspondence to: Il Ju Choi
Received: October 17, 2018; Revised: October 28, 2018; Accepted: October 29, 2018; Published online: November 25, 2018.
© The Korean Journal of Gastroenterology. All rights reserved.

Abstract
Gastric cancer is the most common cancer in Korea and the fifth most common cancer globally. Helicobacter pylori (H. pylori) infection is considered the main etiologic agent for gastric cancer development. Most regional guidelines for H. pylori treatment recommend treating the organism to prevent gastric cancer in the high-risk group. However, evidence that such a strategy can also be applied to the general population, especially in terms of the preventive effect and safety, has not been adequately presented yet. Although a meta-analysis in the general population suggested effectiveness in decreasing gastric cancer incidence, individual studies should be critically reviewed to evaluate the soundness of the evidence. Recently published, long-term, Korean studies on metachronous gastric cancer prevention ended the controversies from previous short-term studies and confirmed the effectiveness. Currently, further prospective, large, randomized studies are ongoing in the general population and will provide more definitive, high-level evidence on this gastric cancer prevention strategy in the next decade.
Keywords: Helicobacter pylori; Stomach neoplasms


This Article


Author ORCID Information

Stats or Metrics
  • View: 512
  • Download: 555

Services
Social Network Service

e-submission

Archives

Official Journal of

Indexed/Covered by

  • thomson reuters
  • pubmedcentral
  • koreamed
  • crossref
  • crossref
  • synepse
  • kofst
  • DOAJ
  • ORCID